Media coverage of drug regulatory agencies' safety advisories: a case study of citalopram and denosumab

Alice Fabbri, Mary O'Keeffe, Ray Moynihan, Mathias Møllebaek, Annim Mohammad, Alice Bhasale, Lorri Puil, Barbara Mintzes

Research output: Contribution to journalArticleResearchpeer-review

Abstract

AIMS: Drug regulators issue safety advisories to warn clinicians and the public about new evidence of harmful effects of medicines. It is unclear how often these messages are covered by the media. Our aim was to analyse the extent of media coverage of two medicines that were subject to safety advisories from 2007 to 2016 in Australia, Canada, United Kingdom and United States.

METHODS: Two widely-used medicines to treat mental health or physical conditions were selected: citalopram and denosumab. Media reports were identified by searching LexisNexis and Factiva. Reports were included if they stated at least one health benefit or harm. A content analysis of the reports was conducted.

RESULTS: In total, 195 media reports on citalopram and 239 on denosumab were included. For citalopram, 43.1% (84/195) of the reports mentioned benefits, 85.6% (167/195) mentioned harms and 9.7% (19/195) mentioned the harm described in the advisories (cardiac arrhythmia). For denosumab, 94.1% (225/239) of the reports mentioned benefits and 39.7% (95/239) mentioned harms. The harms described in the advisories were rarely mentioned: 10.9% (26/239) of the reports mentioned osteonecrosis and ≤5% mentioned any of the other harms (atypical fractures, hypocalcemia, serious infections, and dermatologic reactions).

CONCLUSIONS: We found limited media coverage of the harms highlighted in safety advisories. Almost two-thirds of the media stories on denosumab did not include any information about harms, despite the many advisories during this time frame. Citalopram coverage covered harms more often but rarely mentioned cardiac arrhythmias. These findings raise questions about how to better ensure that regulatory risk communications reach the general public.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusE-pub ahead of print - 17 Feb 2020

Fingerprint Dive into the research topics of 'Media coverage of drug regulatory agencies' safety advisories: a case study of citalopram and denosumab'. Together they form a unique fingerprint.

  • Cite this